Manders, Peggy <br/><br/>
Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.  [electronic resource] 

 -  Cancer  Aug 2004 
 - 486-94 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Standard No.: </label>10.1002/cncr.20374  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Age Distribution<br/>Aged<br/>Analysis of Variance<br/>Biomarkers, Tumor--blood<br/>Biopsy, Needle<br/>Breast Neoplasms--blood<br/>Carcinoma--blood<br/>Cohort Studies<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Humans<br/>Lymph Nodes--pathology<br/>Lymphatic Metastasis<br/>Middle Aged<br/>Multivariate Analysis<br/>Neoplasm Invasiveness--pathology<br/>Neoplasm Staging<br/>Plasminogen Activator Inhibitor 1--blood<br/>Probability<br/>Prognosis<br/>Proportional Hazards Models<br/>Retrospective Studies<br/>Risk Assessment<br/>Survival Analysis<br/>Urokinase-Type Plasminogen Activator--blood